Genomma Lab Internacional, S.A.B. de C.V.
LABB
Rank in Stocks
#9437
Genomma Lab Internacional, S.A.B. de C.V., along with its subsidiary companies,... Genomma Lab Internacional, S.A.B. de C.V., along with its subsidiary companies, specializes in the formulation, promotion, and worldwide distribution of non-prescription pharmaceuticals and personal hygiene products. The firm's extensive product range covers areas such as skincare, general health and wellness, haircare, pain management, cold and flu remedies, gastrointestinal treatments, sexual health, antiperspirant deodorants, hand sanitizers, rehydration drinks, and shaving essentials. It also provides analgesics, antifungal solutions, and hemorrhoid treatments. These items are sold under numerous recognized brands, including Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, TΓo Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, among others. Incorporated in 1996, Genomma Lab Internacional, S.A.B. de C.V. is headquartered in Mexico City, Mexico.
Share Price
$0.8411339
Last synced: 2026-11-12
Market Cap
$849.22M
Change (1 day)
0.19%
Change (1 year)
-14.28%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Genomma Lab Internacional, S.A.B. de C.V. (LABB)
Category
Healthcare
EPS for Genomma Lab Internacional, S.A.B. de C.V. (LABB)
EPS as of September 2026 TTM: $0.09
According to Genomma Lab Internacional, S.A.B. de C.V.'s latest financial reports, its current EPS (TTM) is $0.09. At the end of 2025 the company had an EPS of $0.09, an increase over its 2024 EPS of $0.07.
EPS history for Genomma Lab Internacional, S.A.B. de C.V. from 2005 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.09 | 2.56% |
| 2025 | $0.09 | 23.62% |
| 2024 | $0.07 | 11.26% |
| 2023 | $0.07 | -7.37% |
| 2022 | $0.07 | 13.41% |
| 2021 | $0.06 | -9.30% |
| 2020 | $0.07 | 76.52% |
| 2019 | $0.04 | -28.00% |
| 2018 | $0.06 | -19.35% |
| 2017 | $0.07 | -182.67% |
| 2016 | $-0.08 | 36.82% |
| 2015 | $-0.06 | -164.91% |
| 2014 | $0.09 | -27.42% |
| 2013 | $0.13 | 11.40% |
| 2012 | $0.11 | 21.46% |
| 2011 | $0.09 | 14.81% |
| 2010 | $0.08 | 49.82% |
| 2009 | $0.06 | 54.93% |
| 2008 | $0.04 | 7.58% |
| 2007 | $0.03 | 62.56% |
| 2006 | $0.02 | -297.09% |
| 2005 | $-0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | 6,943.77% |
DE
|
|
| $6.08 | 6,484.62% |
DE
|
|
| $1.55 | 1,579.96% |
JP
|
|
| $3.66 | 3,865.33% |
CH
|
|
| $0.45 | 387.54% |
IL
|
Questions about Genomma Lab Internacional, S.A.B. de C.V.'s earnings per share (EPS)
What is Genomma Lab Internacional, S.A.B. de C.V.'s earnings per share (EPS)?
Genomma Lab Internacional, S.A.B. de C.V.'s earnings per share (EPS) over the last twelve months is $0.09, as of Sep 2026.
What was Genomma Lab Internacional, S.A.B. de C.V.'s earnings per share (EPS) in 2025?
In 2025, Genomma Lab Internacional, S.A.B. de C.V.'s earnings per share (EPS) was $0.09, 28.57% more than in 2024 ($0.07).
How has Genomma Lab Internacional, S.A.B. de C.V.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Genomma Lab Internacional, S.A.B. de C.V.'s earnings per share (EPS) went from $0.07 to $0.09, an average growth of 5.15% a year.
How does Genomma Lab Internacional, S.A.B. de C.V.'s earnings per share (EPS) compare with similar companies?
Genomma Lab Internacional, S.A.B. de C.V.'s earnings per share (EPS) ($0.09) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.